Table TDI-26. Polydrug use among all clients entering outpatient treatment - summary over all countries supplying data for 2003 of most frequently used secondary drugs, as percentages of primary users of cannabis, opiates, cocaine or other stimulants

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).

Table TDI-26. Polydrug use among all clients entering outpatient treatment - summary over all countries supplying data for 2003 of most frequently used secondary drugs, as percentages of primary users of cannabis, opiates, cocaine or other stimulants
Primary drug	Number of clients using primary drug	Opiates	Cocaine	Other stimulants	Hypnotics, sedatives	Hallucinogens	Volatile inhalants	Cannabis	Alcohol	Others
Opiates	17020	3.7	11.6	5.0	5.3	1.2	0.5	46.6	24.4	1.7
Cocaine	3563	12.6	12.6	5.7	1.4	0.2	0.2	39.6	36.5	3.2
Other Stimulants	2031	11.8	5.6	7.3	5.4	3.5	1.8	43.2	19.9	1.6
Cannabis	13013	1.1	2.2	5.7	1.2	0.9	0.7	63.0	23.8	1.4
Notes: Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients Opiates include: heroin, methadone, other opiates; Cocaine includes: Cocaine CIH, crack cocaine; Stimulants include: amphetamines, MDMA and derivates, other stimulants: Cannabis can include herb or resin. For each client up to four secondary drugs can be reported A number of the clients report using the same drug both as primary and secondary drug, particulary for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany Source: 2004 REITOX National Reports – see [Table TDI-19]

Data filter | tditab26-en.xml